

COMMENT ON: USE OF ANKAFERD BLOOD STOPPER FOR CONTROLLING ACTIVELY BLEEDING FUNDAL VARICES

Dear Sir,

We read with interest the recent case report by Okten et al⁽¹⁾ showing the successful haemostatic effects of Ankaferd Blood Stopper (ABS) in a patient with fundal variceal haemorrhage. In their report, the authors proved the efficiency of this novel haemostatic agent, even in patients with gastrointestinal bleeding (GIB) due to fundal varices. They concluded that in serious bleeding gastric fundal varices, ABS can act as a bridge in the absence or unavailability of definitive therapies. In addition to the proposed mechanisms of ABS in GIB, we would like to draw attention to a possible underlying mechanism for this antihaemorrhagic effect of ABS, which we think is important in interpreting their results.

As already mentioned by the authors, the most well-known mechanism of action of ABS is promoting the formation of an encapsulated protein mesh that acts as an anchor for erythrocyte aggregation without significantly interfering with individual coagulation factors.^(2,3) Although this proposed mechanism is noteworthy in several respects, there is a growing body of evidence suggesting the role of ABS in cellular apoptotic response modulation to haemorrhagic stress, as well as its haemostatic haemodynamic activity.⁽⁴⁾ Apart from erythrocyte aggregation, ABS has many effects on proteins in the tissue and blood, leading to dose-dependent reversible protease-activated receptor (PAR)-1 down-regulation. A sustained PAR-1 down-regulation in the presence of lipopolysaccharides is induced by ABS. These findings are compatible with other investigations focusing on the endothelial haemostatic molecules, EPCR and PAI-1. ABS may act as a topical biological response modifier with anti-haemorrhagic actions.⁽⁵⁾ Moreover, ABS-induced formation of the protein network has several essential components. Vital erythroid aggregation takes place in conjunction with the spectrin and ankyrin receptors on red blood cell membranes. Essential erythroid proteins (cyclic AMP response element-binding protein, actin-depolymerisation factor, ankyrin recurrent and FYVE bundle containing protein 1, interferon-stimulated response element, spectrin alpha, actin-depolymerising factor, mitochondrial NADP⁺ dependent malic enzyme) are included in the protein library of ABS. These regulator molecules affect distinct steps of cellular proliferation such as cell vascular haemostasis, angiogenesis, signal transduction, apoptosis, inflammation, acute phase reaction and several metabolic molecular pathways. ABS also upregulates the GATA/FOG transcription system, which affects erythroid functions and urotensin II.⁽⁶⁾ Urotensin II is also an essential component of ABS and acts as a link between active erythroid cells, adhesive proteins and injured vascular endothelium.⁽⁵⁻⁷⁾

In conclusion, ABS could have an efficient place for the 'difficult-to-manage' subtypes of gastrointestinal bleedings. ABS may serve as an adjuvant and/or primary agent for these situations, even in patients with variceal haemorrhage.

Yours sincerely,

Yavuz Beyazit

Abdurrahim Sayilir

Burak Suvak

Murat Kekilli

Adnan Tas

Department of Gastroenterology
Turkiye Yuksek Ihtisas Training and Research Hospital
TR-06100
Ankara
Turkey
Email: yavuzbeyaz@yahoo.com


REFERENCES

1. Okten S, Kurt M, Onal I K, Haznedaroglu IC. Use of Ankaferd Blood Stopper for controlling actively bleeding fundal varices. Singapore Med J 2011; 52:e10-11.
2. Goker H, Haznedaroglu IC, Ercetin S, et al. Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper. J Int Med Res 2008; 36:163-70.
3. Haznedaroglu BZ, Haznedaroglu IC, Walker SL, et al. Ultrastructural and morphological analyses of the in vitro and in vivo hemostatic effects of Ankaferd Blood Stopper. Clin Appl Thromb Hemost 2010; 16:446-53.
4. Huri E, Haznedaroglu IC, Akgul T, et al. Biphasic effects of ankaferd blood stopper on renal tubular apoptosis in the rat partial nephrectomy model representing distinct levels of hemorrhage. Saudi Med J 2010; 30:864-8.
5. Haznedaroglu IC. Molecular basis of the pleiotropic effect of Ankaferd Blood Stopper. IUBMB Life 2009; 61:290.
6. Beyazit Y, Kurt, M, Kekilli M, Goker H, Haznedaroglu IC. Evaluation of hemostatic effects of Ankaferd as an alternative medicine. Altern Med Rev 2010; 15:329-36.
7. Demiralp DO, Haznedaroglu IC, Akar N. Functional proteomic analysis of Ankaferd Blood Stopper. Turk J Hematol 2010; 27:70-7.

Editor's Note: The authors, Okten et al, have declined to comment on the above letter.

RESUSCITATION ISSUE

COMING SOON TO SMJ



Cardiac arrest in the skies
Chest-compression only CPR or good
quality 30:2 CPR?
Brain attack: needing resuscitation
Controlled hypothermia in post-resuscitation
management: what is so cool about it?
The post-resuscitation bundle

And many more